Huntington's drug votoplam tested for Long-Term safety
NCT ID NCT06254482
First seen Nov 21, 2025 · Last updated May 22, 2026 · Updated 23 times
Summary
This study looks at the long-term safety and effects of the drug votoplam in people with Huntington's disease. About 144 participants who completed a previous votoplam study will receive the drug for up to 48 months. Researchers will monitor side effects and measure changes in brain volume, disease symptoms, and huntingtin protein levels.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HUNTINGTON DISEASE are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Novartis Investigative Site
Clayton, 3168, Australia
-
Novartis Investigative Site
Westmead, 2145, Australia
-
Novartis Investigative Site
Innsbruck, 6020, Austria
-
Novartis Investigative Site
Ottawa, K1Y 4E9, Canada
-
Novartis Investigative Site
Angers, 49100, France
-
Novartis Investigative Site
Marseille, 13385, France
-
Novartis Investigative Site
Paris, 75013, France
-
Novartis Investigative Site
Berlin, 10117, Germany
-
Novartis Investigative Site
Bochum, 44791, Germany
-
Novartis Investigative Site
Münster, 48149, Germany
-
Novartis Investigative Site
Ulm, 89081, Germany
-
Novartis Investigative Site
Bologna, 40139, Italy
-
Novartis Investigative Site
Milan, 20133, Italy
-
Novartis Investigative Site
San Giovanni Rotondo, 71013, Italy
-
Novartis Investigative Site
Leiden, 2333 ZA, Netherlands
-
Novartis Investigative Site
Christchurch, 8011, New Zealand
-
Novartis Investigative Site
Barakaldo, 48903, Spain
-
Novartis Investigative Site
Barcelona, 8025, Spain
-
Novartis Investigative Site
Burgos, 90550, Spain
-
Novartis Investigative Site
Madrid, 28034, Spain
-
Novartis Investigative Site
Birmingham, B15 2FG, United Kingdom
-
Novartis Investigative Site
Cardiff, CF14 4XW, United Kingdom
-
Novartis Investigative Site
London, WC1N 3BG, United Kingdom
-
Novartis Investigative Site
Manchester, M13 9WL, United Kingdom
Conditions
Explore the condition pages connected to this study.